The AAV-LRRK2 gene delivery model uses viral vectors to deliver wild-type or mutant LRRK2 to specific brain regions, providing a flexible system for studying LRRK2 pathogenesis and therapeutic intervention.
Vector Design
flowchart TD
models_aav_lrrk2_gene_delivery["AAV-LRRK2 Gene Delivery Model"]
style models_aav_lrrk2_gene_delivery fill:#4fc3f7,stroke:#333,color:#000
models_aav_lrrk2_gen_0["Vector Design"]
models_aav_lrrk2_gene_delivery -->|"includes"| models_aav_lrrk2_gen_0
style models_aav_lrrk2_gen_0 fill:#81c784,stroke:#333,color:#000
models_aav_lrrk2_gen_1["AAV Serotypes"]
models_aav_lrrk2_gene_delivery -->|"includes"| models_aav_lrrk2_gen_1
style models_aav_lrrk2_gen_1 fill:#ef5350,stroke:#333,color:#000
models_aav_lrrk2_gen_2["Promoters"]
models_aav_lrrk2_gene_delivery -->|"includes"| models_aav_lrrk2_gen_2
style models_aav_lrrk2_gen_2 fill:#ffd54f,stroke:#333,color:#000
models_aav_lrrk2_gen_3["LRRK2 Variants"]
models_aav_lrrk2_gene_delivery -->|"includes"| models_aav_lrrk2_gen_3
style models_aav_lrrk2_gen_3 fill:#ce93d8,stroke:#333,color:#000
models_aav_lrrk2_gen_4["Wild-Type LRRK2"]
models_aav_lrrk2_gene_delivery -->|"includes"| models_aav_lrrk2_gen_4
style models_aav_lrrk2_gen_4 fill:#4fc3f7,stroke:#333,color:#000
models_aav_lrrk2_gen_5["Disease-Associated Mutants"]
models_aav_lrrk2_gene_delivery -->|"includes"| models_aav_lrrk2_gen_5
style models_aav_lrrk2_gen_5 fill:#81c784,stroke:#333,color:#000
AAV Serotypes ... The AAV-LRRK2 gene delivery model uses viral vectors to deliver wild-type or mutant LRRK2 to specific brain regions, providing a flexible system for studying LRRK2 pathogenesis and therapeutic intervention.
Vector Design
Mermaid diagram (expand to render)
AAV Serotypes | Serotype | CNS Tropism | Efficiency | Clinical Relevance |
CMV : Strong, constitutive expressionSynapsin : Neuron-specific expressionGFAP : Astrocyte-specific expressionMeCP2 : Neuronal activity-dependentLRRK2 Variants
Wild-Type LRRK2
Overexpression of normal LRRK2 protein
Used to study gain-of-function mechanisms
Typical expression: 2-5x endogenous levels
Disease-Associated Mutants | Mutation | Effect | Frequency in PD | Model Use |
Pathological Mechanisms
Kinase Hyperactivity The G2019S mutation increases LRRK2 kinase activity 2-3 fold:
Substrate phosphorylation : Enhanced phosphorylation of Rab proteins (Rab8A, Rab10, Rab12)Lysosomal dysfunction : Altered lysosomal trafficking and functionAutophagy impairment : Dysregulated autophagic fluxNeurite pathology : Reduced neurite length and branching
Synaptic Dysfunction
Altered synaptic vesicle dynamics
Impaired dopamine release and reuptake
Synaptic α-synuclein accumulation
Research Applications
Therapeutic Testing The model enables testing of:
LRRK2 kinase inhibitors : [DNL151](/therapeutics/dnl151), [DLB-45365](/therapeutics/lrrk2-kinase-targeting-therapies)Antisense oligonucleotides : [BIIB100](/therapeutics/lrrk2-antisense-therapy)Autophagy enhancers : [Trehalose](/therapeutics/trehalose-neurodegeneration), [rapamycin](/therapeutics/mtor-inhibitor-therapy)Neuroprotective agents : [CoQ10](/therapeutics/mitochondrial-biogenesis-inducers), [nicotinamide](/therapeutics/nad-boosters-neurodegeneration)
Mechanism Studies
Rab pathway : Identify downstream effectors of LRRK2 hyperactivationCell-type specificity : Understand which neurons are most vulnerableInteraction with α-synuclein : Synergistic pathology with [SNCA](/genes/snca)Advantages and Limitations
Advantages
Temporal control : Expression can be induced at specific timesSpatial control : Targeting to specific brain regionsDose-titratable : Variable viral doses control expression levelNo developmental effects : Adult-onset expressionCompatible with other models : Can combine with transgenic or toxin modelsLimitations
Acute overexpression : Not a chronic developmental modelNon-physiological levels : Expression may exceed endogenous levelsImmune response : AAV capsid immunity in some subjectsVariable transduction : Batch-to-batch and animal-to-animal variationExperimental Design
Standard Protocol
Stereotactic injection : AAV into striatum or substantia nigraExpression timeline : Peak expression at 2-4 weeksAnalysis window : 4-12 weeks post-injectionBehavioral testing : Rotarod, cylinder, gait analysis
Controls
AAV-GFP or AAV-lacZ control vector
Isogenic wild-type LRRK2 control
Uninjected contralateral hemisphere
[LRRK2 G2019S Transgenic](/models/lrrk2-g2019s-transgenic-mouse) — Genetic model](/models)
[AAV-α-Synuclein](/experiments/aav-serotype-lrrk2-knockdown) — Combined model](/experiments)
[iPSC-derived neurons](/models/ipsc-derived-dopaminergic-neurons) — Patient-derived
References
[Daher et al., 2014 - AAV-mediated LRRK2 overexpression in mice](https://doi.org/10.1016/j.neurobiolaging.2014.05.032)
[Volpicelli-Daley et al., 2016 - LRRK2 and α-synuclein interaction](https://doi.org/10.3233/JAD-160313)
[Steger et al., 2016 - LRRK2 kinase activity in vivo](https://doi.org/10.1038/ncomms12332)
[Blandini et al., 2020 - AAV-LRRK2 models and therapeutic screening](https://doi.org/10.1016/j.neuropharm.2020.108006)
[Javed et al., 2019 - LRRK2-targeted therapies in preclinical models](https://doi.org/10.1002/mds.27723)
Show full description